FEATURED COMPANIES
- Arronax-Nantes
- Daihan Pharma Co Ltd
- Galenica Senese S.R.L
- Iso-Analytical Ltd.
- Lantheus Medical Imaging
- Pharmalucence Inc.
Chemical substances that improve the visibility of specific organs, tissues or blood vessels during a diagnostic imaging investigation are known as medical imaging agents that comprise contrast agents and nuclear medicine. These substances are administered directly through veins, arteries, and joints or consumed orally. X-ray and computed tomography (CT) imaging exams make use of iodinated and barium based contrast agents, whereas, Gadolinium-based contrast agents are preferred in MRI (Magnetic Resonance Imaging). These substances improve the reporting or accuracy of how internal structures of the body are working and any associated abnormalities. Ultrasound scans makes use of special contrast agents called microbubbles which strongly interact with the ultrasound beam and enhances the details of the heart, liver, and kidney. Nuclear medicine is a highly multi-disciplined medical imaging specialty sector that uses small amounts of radioactive material to diagnose diseases. According to the author's estimates, the Medical imaging agents market is expected to grow at mid-single-digit CAGR from 2019 to 2026 to reach $12,290.7 million by 2026.
Medical imaging agents global market by molecule/isotope segmented into contrast agents and nuclear medicine. According to the author, the contrast agents' global market is expected to grow at a mid-single-digit CAGR from 2019 to 2026. The contrast agents global market by molecule is segmented into Iodine based [Ionic (Monomeric and Dimeric), Non-Ionic (Monomeric and Dimeric)], Gadolinium-based contrast agents [Macrocyclic (Ionic and Non-Ionic), Linear (Ionic and Non-Ionic)], microbubble based contrast agent and others which include Barium, iron and dyes. Iodine-based contrast agents market held the largest market revenue in 2019 and the microbubble segment is the fastest-growing segment at double-digit CAGR from 2019 to 2026 due to expansion in disease indications. Based on ionicity, the Iodine-based contrast agent is segmented into ionic and non-ionic. Non-Ionic Iodine-based contrast agents market accounted for the largest share in 2019. Non-ionic iodine contrast agents are used more because of lower osmolality, they are better tolerated and another advantage is that they appear to have less toxicity. Ionic Iodine based contrasts are further segmented by its chemical structure into monomers and dimers. Monomers market accounted for the largest share in 2019. Non-Ionic Iodine based contrasts are further segmented by its chemical structure into monomeric and dimeric. Monomerics market accounted for the largest share in 2019 and is projected to grow at a low single-digit CAGR from 2019 to 2026 as they are safer and tolerable when compared to ionic contrast agents and low osmolar agents do not dissociate into a particle in solution and helps in reducing the neurotoxicity.
As estimated by the author, the nuclear medicine global market is poised to grow at a mid single-digit CAGR from 2019 to 2026. Increased radioisotopes applications, rise in public awareness, use of SPECT/CT and PET/CT imaging scans, the abundance of radiopharmaceuticals, advancement in imaging technology (hybrid imaging) is boosting the nuclear medicine market growth. Also, increasing need in emerging markets, production of radiopharmaceuticals from cyclotrons, efficient diagnosis and treatments, emerging radio isotopes and replacement of old/traditional equipment are the opportunities likely to propel the growth of nuclear medicine market.
The nuclear medicine global market by isotopes are segmented into Technetium (Tc-99m), Thallium (Tl-201), Gallium (Ga-67), Iodine (I-123), Xe-133, Samarium (Sm-153), Rhenium (Re-186), Fluorodeoxyglucose (18F-FDG), Gallium (Ga-68), Rubidium (Rb-82) and others. Technetium (Tc-99m) isotope market held largest revenue in 2019 and expected to grow at mid-single-digit CAGR from 2019 to 2026 and Fluorodeoxyglucose (18F-FDG) is projected to grow at a strong CAGR from 2019 to 2026 due to accuracy.
The Medical imaging agents market by modality is segmented into X-Ray/CT, MRI, Ultrasound, SPECT and PET. X-Ray/CT market held the largest market revenue in 2019 and the ultrasound segment is growing rapidly at high double-digit CAGR from 2019 to 2026 due to increased use in diagnostic procedures especially echocardiography, focal liver lesions and ultrasonography of urinary tract.
The Medical imaging agents market by applications is segmented into cardiovascular, cancer, gastrointestinal, musculoskeletal, neurology, nephrology, obstetrics & gynecology, pulmonary, hepatology and others which include the neck, bone, and salivary gland imaging. The cardiovascular market accounted for the largest share in 2019 and cancer is the fastest growing market with projected single digit CAGR growth from 2019 to 2026 due to increasing in cancer imaging such as lung, thyroid and breast cancer imaging procedures using Iodine, Gadolinium and microbubble contrast agents and radiopharmaceuticals. Medical imaging agents market by route of administration is segmented into intravascular, oral, rectal and others, which include intraosseous, intrathecal and intravesical. Intravascular accounted for the largest share in 2019 and is the fastest-growing market with projected mid-single-digit CAGR from 2019 to 2026 due to an increase in incidence and prevalence of cardiovascular, cancer, neurology, nephrology related conditions which require Iodine, Gadolinium, microbubble contrast agent and nuclear medicine to be administered intravascular.
Medical imaging agents market by imaging is segmented into diagnostics and interventional imaging. Diagnostic imaging commanded the largest revenue in 2019 and expected to grow at a CAGR low single-digit CAGR from 2019 to 2026. The interventional imaging segment is estimated to grow rapidly at double-digit CAGR from 2019 to 2026 due to an increase in image guide procedures and an increase in the aging population who usually opt minimally invasive procedures.
Medical imaging based on the end-user market is segmented into hospitals, diagnostic & ambulatory surgical centers and others which include academic and research institutes. Hospitals market accounted largest share in 2019, the rising demand for the diagnosis using CT or X-Ray, MRI, ultrasound, SPECT and PET imaging procedures due to an increase in incidence and prevalence of diseases, the ready availability of cyclotrons for the generation of isotopes and presence of trained technicians who can handle radioisotopes. Diagnostic & Ambulatory surgical centers are the fastest-growing market and are estimated to grow at mid-single-digit CAGR from 2019 to 2026 due to increase in the number of diagnostic procedures related to musculoskeletal (arthroscopy, imaging of spine), gastrointestinal (imaging of the abdomen, GI tract) and obstetrics & gynecology (hysterosalpingography).
Geographically, the North America region commanded the largest revenue in 2019 due to favorable reimbursement coverage, technological advancement in equipment, increased utilization of fusion imaging and an increase in incidence and prevalence of disease conditions due to changes in lifestyle, obesity has led the market growth in this region. However, the Asia-Pacific region is the fastest-growing market and is expected to grow at double-digit CAGR from 2019 to 2026 due to increased healthcare awareness, improved economic growth, large patient pool, and rising aged population.
The Medical imaging agents' global market is a competitive market and all the existing players in this market are involved in developing new and advanced products to maintain their market shares and also acquiring companies for product expansion. Some of the key players in the Medical imaging agents global market are Bayer Group (Germany), Bracco Group (Italy), Curium Pharma (France), Cardinal Health (U.S), Fujifilm Holding Corporation (Japan), Fujipharma Co. Ltd (Japan), GE Company (GE Healthcare) (U.S.), Guerbet (France), Jubilant Life science (India), Lantheus Medical Imaging (U.S.) and Novartis International AG (Advanced accelerator) (Switzerland).
The report provides an in-depth market analysis of the above-mentioned segments across the following regions:
- North America
- Europe
- Asia-Pacific
- Rest of the World (RoW)
FEATURED COMPANIES
- Arronax-Nantes
- Daihan Pharma Co Ltd
- Galenica Senese S.R.L
- Iso-Analytical Ltd.
- Lantheus Medical Imaging
- Pharmalucence Inc.
1 Executive Summary
2 Introduction
2.1 Key Takeaways
2.2 Report Scope
2.3 Report Description
2.4 Markets Covered
2.5 Stakeholders
2.6 Research Methodology
2.6.1 Market Size Estimation
2.6.2 Market Crackdown And Data Triangulation
2.6.3 Secondary Sources
2.6.4 Primary Sources
2.6.5 Key Data Points From Secondary Sources
2.6.6 Key Data Points From Primary Sources
2.6.7 Assumptions
3 Market Analysis
3.1 Introduction
3.2 Market Segmentation
3.3 Factors Influencing Market
3.3.1 Drivers And Opportunities
3.3.1.1 Increasing Demand For Imaging Agent-Assisted Diagnostic Procedures
3.3.1.2 Production Of Radiopharmaceuticals From Cyclotrons
3.3.1.3 The Growth Of Medical Imaging Technologies In Emerging Markets
3.3.1.4 Usage Of Hybrid Imaging
3.3.1.5 Favorable Reimbursement
3.3.2 Restraints And Threats
3.3.2.1 Side Effect Associated With Medical Imaging Agents
3.3.2.2 The Shorter Half-Life Of Radiopharmaceuticals
3.3.2.3 Shortage Of Radiologist And Qualified Technicians
3.3.2.4 High Cost And Supply Shortage Of Isotopes
3.3.2.5 Stringent Regulations For Manufacturing And Marketing Of Medical Imaging Agents
3.4 Regulatory Guidelines
3.4.1 United States
3.4.2 Europe
3.4.3 China
3.4.4 Japan
3.4.5 India
3.4.6 South Korea
3.5 Reimbursement Table
3.6 Upcoming Technology
3.6.1 Near-Infrared Fluorescent Imaging
3.6.2 Targeted Contrast Agent
3.7 Clinical Trials
3.7.1 Contrast Agents Clinical Trial
3.7.1.1 Gadolinium Based Contrast Agents
3.7.1.2 Iodinated Contrast Agents
3.7.1.3 Iron Oxide Contrast Agents
3.7.1.4 Manganese Based Contrast Agents
3.7.2 Nuclear Medicine Clinical Trials
3.7.2.1 Pet Based Imaging Agents (Fdg)
3.7.2.2 F-18 Based Agents
3.7.2.3 Xe-133 Based Agents
3.7.2.4 Ga-68 Based Agents
3.8 Supply Chain Analysis Of Nuclear Medicine
3.8.1 Reactors
3.8.2 Processing Facility
3.8.3 Generators Manufacturing Units
3.8.4 Hospitals And Central Radio Pharmacies
3.9 List Of Current Irradiators And Processors Of Technitum 99
3.10 Supply Chain Analysis Of Contrast Agents
3.11 Patent Trends
3.12 Porter’S Five Force Analysis
3.12.1 Threat Of New Entrants
3.12.2 Threat Of Substitutes
3.12.3 Bargaining Power Of Suppliers
3.12.4 Bargaining Power Of Buyers
3.12.5 Rivalry Among Existing Competitors
3.13 Market Share Analysis
3.13.1 Market Share Analysis By Major Players
3.13.2 Market Share Analysis Of Contrast Agents
3.13.3 Market Share Analysis Of Nuclear Medicine
3.13.4 Market Share Analysis Of Mri
3.13.5 Market Share Analysis Of X-Ray/Ct
3.13.6 Market Share Analysis Of Ultrasound Agents
3.13.7 Market Share Analysis Of Spect Agents
3.13.8 Market Share Analysis Of Pet Agents
3.14 Medical Imaging Agents Global Consumption Data
3.14.1 X-Ray/Ct Global Comsumption Volume
3.14.2 Mri Global Comsumption Volume
3.14.3 Ultrasound Global Comsumption Volume
3.15 Medical Imaging Procedural Volume
3.15.1 X-Ray/Ctcontrast Agents Global Procedural Volume
3.15.2 Mri Contrast Agents Global Procedural Volume
3.15.3 Ultrasound Contrast Agents Global Procedural Volume
4 Medical Imaging Agents Global Market, By Molecule/Isotope
4.1 Introduction
4.2 Contrast Agents
4.2.1 Iodinated Contrast Agents
4.2.1.1 Iodinated Ionic Contrast Agents
4.2.1.1.1 Monomers
4.2.1.1.2 Dimer
4.2.1.2 Iodinated Non-Ionic Contrast Agents
4.2.1.2.1 Monomer
4.2.1.2.2 Dimer
4.2.2 Gadolinium-Based Contrast Agents
4.2.2.1 Macrocyclic Contrast Agents
4.2.2.1.1 Ionic Macrocyclic Contrast Agents
4.2.2.1.2 Non-Ionic Macrocyclic Contrast Agents
4.2.2.2 Linear Gadolinium Based Contrast Agents
4.2.2.2.1 Ionic Linear Contrast Agents
4.2.2.2.2 Non-Ionic Linear Contrast Agents
4.2.3 Microbubble Based Contrast Agents
4.2.4 Others Contrast Agents
4.3 Nuclear Medicine
4.3.1 Technetium (Tc-99M)
4.3.2 Thallium (Tl-201)
4.3.3 Gallium (Ga-67)
4.3.4 Iodine (I-123)
4.3.5 Xenon (Xe-133)
4.3.6 Samarium (Sm-153)
4.3.7 Rhenium (Re-186)
4.3.8 Fluorodeoxyglucose (18F-Fdg)
4.3.9 Gallium (Ga-68)
4.3.10 Rubidium (Rb-82)
4.3.11 Others
5 Medical Imaging Agents Global Market, By Modality
5.1 Introduction
5.2 X-Ray/Computed Tomography (Ct)
5.3 Magnetic Resonance Imaging (Mri)
5.4 Ultrasound
5.5 Single Photo Emission Computed Tomography (Spect)
5.6 Positron Emission Tomography(Pet)
6 Medical Imaging Agents Global Market, By Application
6.1 Introduction
6.2 Cardiovascular
6.3 Cancer
6.4 Gastrointestinal
6.5 Musculoskeletal
6.6 Neurology
6.7 Nephrology
6.8 Obstetrics And Gynecology
6.9 Pulmonary
6.10 Hepatology
6.11 Others
7 Medical Imaging Agents Global Market, By Route Of Administration
7.1 Introduction
7.2 Intravascular
7.3 Oral
7.4 Rectal
7.5 Others
8 Medical Imaging Agents Global Market, By Imaging
8.1 Introduction
8.2 Diagnostic Imaging
8.3 Interventional Imaging
9 Medical Imaging Agents Global Market, By End-Users
9.1 Introduction
9.2 Hospital
9.3 Diagnostic & Ambulatory Surgical Centers
9.4 Other End-User
10 Regional Analysis
10.1 Introduction
10.2 North America
10.2.1 U.S.
10.2.2 Rest Of N.A.
10.3 Europe
10.3.1 Germany
10.3.2 France
10.3.3 U.K.
10.3.4 Rest Of Europe
10.4 Asia-Pacific
10.4.1 China
10.4.2 Japan
10.4.3 South Korea
10.4.4 Rest Of Asia-Pacific
10.5 Rest Of The World
10.5.1 Turkey
10.5.2 Brazil
10.5.3 Others
11 Competitive Landscape
11.1 Introduction
11.2 Collaborations, Agreements And Partnership
11.3 Approvals
11.4 Other Key Development
12 Major Player Profiles
12.1 Bayer Group
12.1.1 Overview
12.1.2 Financials
12.1.3 Product Portfolio
12.1.4 Key Developments
12.1.5 Business Strategy
12.1.6 SWOT Analysis
12.2 Bracco Group
12.2.1 Overview
12.2.2 Financials
12.2.3 Product Portfolio
12.2.4 Key Developments
12.2.5 Business Strategy
12.2.6 SWOT Analysis
12.3 Cardinal Health Inc.
12.3.1 Overview
12.3.2 Financials
12.3.3 Product Portfolio
12.3.4 Key Developments
12.3.5 Business Strategy
12.3.6 SWOT Analysis
12.4 Curium Pharma
12.4.1 Overview
12.4.2 Financials
12.4.3 Product Portfolio
12.4.4 Key Developments
12.4.5 Business Strategy
12.4.6 SWOT Analysis
12.5 Fujifilm Holdings Corporation
12.5.1 Overview
12.5.2 Financials
12.5.3 Product Portfolio
12.5.4 Key Developments
12.5.5 Business Strategy
12.5.6 SWOT Analysis
12.6 Fujipharma Co Ltd
12.6.1 Overview
12.6.2 Financials
12.6.3 Product Portfolio
12.6.4 Key Developments
12.6.5 Business Strategy
12.6.6 SWOT Analysis
12.7 GE Company (Ge Healthcare)
12.7.1 Overview
12.7.2 Financials
12.7.3 Product Portfolio
12.7.5 Business Strategy
12.7.6 SWOT Analysis
12.8 Guerbet
12.8.1 Overview
12.8.2 Financials
12.8.3 Product Portfolio
12.8.4 Key Developments
12.8.5 Business Strategy
12.8.6 SWOT Analysis
12.9 Jubilant Lifesciences
12.9.1 Overview
12.9.2 Financials
12.9.3 Product Portfolio
12.9.4 Key Developments
12.9.5 Business Srategy
12.9.6 SWOT Analysis
12.10 Lantheus Medical Imaging Inc.
12.10.1 Overview
12.10.2 Financials
12.10.3 Product Portfolio
12.10.4 Key Developments
12.10.5 Business Strategy
12.10.6 SWOT Analysis
12.11 Novartis (Advance Accelerator Applications S.A.)
12.11.1 Overview
12.11.2 Financials
12.11.3 Product Portfolio
12.11.4 Key Developments
12.11.5 Business Strategy
12.11.6 SWOT Analysis
List of Tables
Table 1 Medical Imaging Agents Global Market Revenue, By Region, (2018-2026) ($Mn)
Table 2 Technetium (Tc-99M) Reactors
Table 3 Current Irradiators Including Those In Transition By 2023
Table 4 Current Processors Including Those In Transition By 2023
Table 5 Potential Irradiations Entering In Period 2018 To 2023
Table 6 Potential Processors Entering In Period 2018 To 2023
Table 7 X-Ray/Ct Contrast Agents Global Consumption, By Region, (2018-2026) (L)
Table 8 Mri Contrast Agents Global Consumption, By Region, (2018-2026) (L)
Table 9 Ultrasound Imaging Agents Global Consumption, By Region, (2018-2026) (L)
Table 10 X-Ray/Ct Contrast Agents Global Procedural Volume, By Region, (2018-2026) (No’S)
Table 11 Mri Contrast Agents Global Procedural Volume, By Region, (2018-2026) (No’S)
Table 12 Ultrasound Contrast Agents Global Procedural Volume, By Region, (2018-2026) (No’S)
Table 13 Spect Global Procedural Volume, By Region, (2018-2026) (No’S)
Table 14 Pet Global Procedural Volume, By Region, (2018-2026) (No)
Table 15 Medical Imaging Agents Global Market Revenue, By Region, (2018-2026) ($Mn)
Table 16 Medical Imaging Agents Global Market Revenue, By Molecule/Isotope, (2018-2026) ($Mn)
Table 17 Contrast Agents Global Market Revenue, By Region, (2018-2026) ($Mn)
Table 18 Contrast Agents Global Market Revenue, By Molecule, (2018-2026) ($Mn)
Table 19 Iodinated Contrast Agents Global Market Revenue, By Region, (2018-2026) ($Mn)
Table 20 Iodinated Contrast Agents Global Market Revenue, By Ionicity, (2018-2026) ($Mn)
Table 21 Iodinated Ionic Contrast Agents Global Market Revenue, By Region, (2018-2026) ($Mn)
Table 22 Ionic Contrast Agents Global Market Revenue, By Chemical Structure, (2018-2026) ($Mn)
Table 23 Monomer Ionic Contrast Agents Global Market Revenue, By Region, (2018-2026) ($Mn)
Table 24 Iodinated Non-Ionic Contrast Agents Global Market Revenue, By Region, (2018-2026) ($Mn)
Table 25 Non-Ionic Contrast Agents Global Market Revenue, By Chemical Structure, (2018-2026) ($Mn)
Table 26 Monomer Non-Ionic Contrast Agents Global Market Revenue, By Region, (2018-2026) ($Mn)
Table 27 Dimer Non-Ionic Contrast Agents Global Market Revenue, By Region, (2018-2026) ($Mn)
Table 28 Gadolinium Based Contrast Agents Global Market Revenue, By Chemical Structure, (2018-2026) ($Mn)
Table 29 Gadolinium Based Contrast Agents Global Market Revenue, By Region, (2018-2026) ($Mn)
Table 30 Macrocyclic Contrast Agents Global Market Revenue, By Region, (2018-2026) ($Mn)
Table 31 Macrocyclic Contrast Agents Global Market Revenue, By Ionicity, (2018-2026) ($Mn)
Table 32 Ionic Macrocyclic Contrast Agents Global Market Revenue, By Region, (2018-2026) ($Mn)
Table 33 Non-Ionic Macrocyclic Contrast Agents Global Market Revenue, By Region, (2018-2026) ($Mn)
Table 34 Linear Gadolinium Based Contrast Agents Global Market Revenue, By Region, (2018-2026) ($Mn)
Table 35 Linear Gadolinium Based Contrast Agents Global Market Revenue, By Ionicity, (2018-2026) ($Mn)
Table 36 Ionic Linear Contrast Agents Global Market Revenue, By Region, (2018-2026) ($Mn)
Table 37 Non-Ionic Linear Contrast Agents Global Market Revenue, By Region, (2018-2026) ($Mn)
Table 38 Microbubble Based Contrast Agents Global Market Revenue, By Region, (2018-2026) ($Mn)
Table 39 Other Contrast Agents Global Market Revenue, By Region, (2018-2026) ($Mn)
Table 40 Nuclear Medicine Global Market Revenue, By Region, (2018-2026) ($Mn)
Table 41 Nuclear Medicine Global Market Revenue, By Isotope, (2018-2026) ($Mn)
Table 42 Technetium (Tc-99M) Isotope Global Market Revenue, By Region, (2018-2026) ($Mn)
Table 43 Thallium (Tl-201) Isotope Global Market Revenue, By Region, (2018-2026) ($Mn)
Table 44 Gallium (Ga-67) Isotope Global Market Revenue, By Region, (2018-2026) ($Mn)
Table 45 Iodine (I-123) Isotope Global Market Revenue, By Region, (2018-2026) ($Mn)
Table 46 Xenon (Xe-133) Isotope Global Market Revenue, By Region, (2018-2026) ($Mn)
Table 47 Samarium (Sm-153) Isotope Global Market Revenue, By Region, (2018-2026) ($Mn)
Table 48 Rhenium (Re-186) Isotope Global Market Revenue, By Region, (2018-2026) ($Mn)
Table 49 Flurodeoxyglucose(18F-Fdg) Global Market Revenue, By Region, (2018-2026) ($Mn)
Table 50 Gallium (Ga-68) Isotope Global Market Revenue, By Region, (2018-2026) ($Mn)
Table 51 Rubidium (Rb-82) Isotope Global Market Revenue, By Region, (2018-2026) ($Mn)
Table 52 Other Isotopes Global Market Revenue, By Region, (2018-2026) ($Mn)
Table 53 Medical Imaging Agents Global Market Revenue, By Modality, (2018-2026) ($Mn)
Table 54 X-Ray/Ct Global Market Revenue, By Region, (2018-2026) ($Mn)
Table 55 Mri Global Market Revenue, By Region, (2018-2026) ($Mn)
Table 56 Ultrasound Global Market Revenue, By Region, (2018-2026) ($Mn)
Table 57 Spect Global Market Revenue, By Region, (2018-2026) ($Mn)
Table 58 Pet Global Market Revenue, By Region, (2018-2026) ($Mn)
Table 59 Medical Imaging Agents Global Market Revenue, By Application, (2018-2026) ($Mn)
Table 60 Cardiovascular Global Market Revenue, By Region, (2018-2026) ($Mn)
Table 61 Cancer Global Market Revenue, By Region, (2018-2026) ($Mn)
Table 62 Gastrointestinal Global Market Revenue, By Region, (2018-2026) ($Mn)
Table 63 Musculoskeletal Global Market Revenue, By Region, (2018-2026) ($Mn)
Table 64 Neurology Global Market Revenue, By Region, (2018-2026) ($Mn)
Table 65 Nephrology Global Market Revenue, By Region, (2018-2026) ($Mn)
Table 66 Obstetrics And Gynecology Global Market Revenue, By Region, (2018-2026) ($Mn)
Table 67 Pulmonary Global Market Revenue, By Region, (2018-2026) ($Mn)
Table 68 Hepatology Global Market Revenue, By Region, (2018-2026) ($Mn)
Table 69 Other Applications Global Market Revenue, By Region, (2018-2026) ($Mn)
Table 70 Medical Imaging Agents Global Market Revenue, By Route Of Administration, (2018-2026) ($Mn)
Table 71 Intravascular Global Market Revenue, By Region, (2018-2026) ($Mn)
Table 72 Oral Global Market Revenue, By Region, (2018-2026) ($Mn)
Table 73 Rectal Global Market Revenue, By Region, (2018-2026) ($Mn)
Table 74 Others Global Market Revenue, By Region, (2018-2026) ($Mn)
Table 75 Medical Imaging Agents Global Market Revenue, By Imaging, (2018-2026) ($Mn)
Table 76 Diagnostic Imaging Global Market Revenue, By Region, (2018-2026) ($Mn)
Table 77 Interventional Imaging Global Market Revenue, By Region, (2018-2026) ($Mn)
Table 78 Medical Imaging Agents Global Market Revenue, By End-User, (2018-2026) ($Mn)
Table 79 Hospital Global Market Revenue, By Region, (2018-2026) ($Mn)
Table 80 Diagnostic & Ambulatory Surgical Centers Global Market Revenue, By Region, (2018-2026) ($Mn)
Table 81 Other End-User Global Market Revenue, By Region, (2018-2026) ($Mn)
Table 82 Medical Imaging Agents Global Market Revenue, By Region, (2018-2026) ($Mn)
Table 83 North America Medical Imaging Agents Market Revenue, By Molecule/Isotope, (2018-2026) ($Mn)
Table 84 North America Contrast Agents Market Revenue, By Molecule, (2018-2026) ($Mn)
Table 85 North America Iodinated Contrast Agents Market Revenue, By Ionicity, (2018-2026) ($Mn)
Table 86 North America Ionic Contrast Agents Market Revenue, By Chemical Structure (2018-2026) ($Mn)
Table 87 North America Non-Ionic Contrast Agents Market Revenue, By Chemical Structure, (2018-2026) ($Mn)
Table 88 North America Gadolinium Based Contrast Agents Market Revenue, By Chemical Structure, (2018-2026) ($Mn)
Table 89 North America Macrocyclic Contrast Agents Market Revenue, By Ionicity, (2018-2026) ($Mn)
Table 90 North America Linear Contrast Agents Market Revenue, By Ionicity, (2018-2026) ($Mn)
Table 91 North America Nuclear Medicine Market Revenue, By Isotope, (2018-2026) ($Mn)
Table 92 North America Medical Imaging Agents Market Revenue, By Modality, (2018-2026) ($Mn)
Table 93 North America Medical Imaging Agents Market Revenue, By Application, (2018-2026) ($Mn)
Table 94 North America Medical Imaging Agents Market Revenue, By Route Of Administration, (2018-2026) ($Mn)
Table 95 North America Medical Imaging Agents Market Revenue, By Imaging, (2018-2026) ($Mn)
Table 96 North America Medical Imaging Agents Market Revenue, By End-User, (2018-2026) ($Mn)
Table 97 North America Medical Imaging Agents Market Revenue, By Country, (2018-2026) ($Mn)
Table 98 Europe Medical Imaging Agents Market Revenue, By Molecule/Isotope, (2018-2026) ($Mn)
Table 99 Europe Contrast Agents Market Revenue, By Molecule, (2018-2026) ($Mn)
Table 100 Europe Iodinated Contrast Agents Market Revenue, By Ionicity, (2018-2026) ($Mn)
Table 101 Europe Ionic Contrast Agents Market Revenue, By Chemical Structure, (2018-2026) ($Mn)
Table 102 Europe Non-Ionic Contrast Agents Market Revenue, By Chemical Structure, (2018-2026) ($Mn)
Table 103 Europe Gadolinium Based Contrast Agents Market Revenue, By Chemical Structure, (2018-2026) ($Mn)
Table 104 Europe Macrocyclic Contrast Agents Market Revenue, By Ionicity, (2018-2026) ($Mn)
Table 105 Europe Linear Contrast Agents Market Revenue, By Ionicity, (2018-2026) ($Mn)
Table 106 Europe Nuclear Medicine Market Revenue, By Isotope, (2018-2026) ($Mn)
Table 107 Europe Medical Imaging Agents Market Revenue, By Modality, (2018-2026) ($Mn)
Table 108 Europe Medical Imaging Agents Market Revenue, By Application, (2018-2026) ($Mn)
Table 109 Europe Medical Imaging Agents Market Revenue, By Route Of Administration, (2018-2026) ($Mn)
Table 110 Europe Medical Imaging Agents Market Revenue, By Imaging (2018-2026) ($Mn)
Table 111 Europe Medical Imaging Agents Market Revenue, By End-User, (2018-2026) ($Mn)
Table 112 Europe Medical Imaging Agents Market Revenue, By Country, (2018-2026) ($Mn)
Table 113 APAC Medical Imaging Agents Market Revenue, By Molecule/Isotope, (2018-2026) ($Mn)
Table 114 APAC Contrast Agents Market Revenue, By Molecule, (2018-2026) ($Mn)
Table 115 APAC Iodinated Contrast Agents Market Revenue, By Ionicity, (2018-2026) ($Mn)
Table 116 APAC Ionic Contrast Agents Market Revenue, By Chemical Structure, (2018-2026) ($Mn)
Table 117 APAC Non-Ionic Contrast Agents Market Revenue, By Chemical Structure, (2018-2026) ($Mn)
Table 118 APAC Gadolinium Based Contrast Agents Market Revenue, By Chemical Structure, (2018-2026) ($Mn)
Table 119 APAC Macrocyclic Contrast Agents Market Revenue, By Ionicity, (2018-2026) ($Mn)
Table 120 APAC Linear Contrast Agents Market Revenue, By Ionicity, (2018-2026) ($Mn)
Table 121 APAC Nuclear Medicine Market Revenue, By Isotope, (2018-2026) ($Mn)
Table 122 APAC Medical Imaging Agents Market Revenue, By Modality, (2018-2026) ($Mn)
Table 123 APAC Medical Imaging Agents Market Revenue, By Application, (2018-2026) ($Mn)
Table 124 APAC Medical Imaging Agents Market Revenue, By Route Of Administration, (2018-2026) ($Mn)
Table 125 APAC Medical Imaging Agents Market Revenue, By Imaging (2018-2026) ($Mn)
Table 126 APAC Medical Imaging Agents Market Revenue, By End-User, (2018-2026) ($Mn)
Table 127 APAC Medical Imaging Agents Market Revenue, By Country, (2018-2026) ($Mn)
Table 128 RoW Medical Imaging Agents Market Revenue, By Molecule/Isotope, (2018-2026) ($Mn)
Table 129 RoW Contrast Agents Market Revenue, By Molecule, (2018-2026) ($Mn)
Table 130 RoW Iodinated Contrast Agents Market Revenue, By Ionicity, (2018-2026) ($Mn)
Table 131 RoW Ionic Contrast Agents Market Revenue, By Chemical Structure, (2018-2026) ($Mn)
Table 132 RoW Non-Ionic Contrast Agents Market Revenue, By Chemical Structure, (2018-2026) ($Mn)
Table 133 RoW Gadolinium Based Contrast Agents Market Revenue, By Chemical Structure, (2018-2026) ($Mn)
Table 134 RoW Macrocyclic Contrast Agents Market Revenue, By Ionicity, (2018-2026) ($Mn)
Table 135 RoW Linear Contrast Agents Market Revenue, By Ionicity, (2018-2026) ($Mn)
Table 136 RoW Nuclear Medicine Market Revenue, By Isotope, (2018-2026) ($Mn)
Table 137 RoW Medical Imaging Agents Market Revenue, By Modality, (2018-2026) ($Mn)
Table 138 RoW Medical Imaging Agents Market Revenue, By Application, (2018-2026) ($Mn)
Table 139 RoW Medical Imaging Agents Market Revenue, By Route Of Administration, (2018-2026) ($Mn)
Table 140 RoW Medical Imaging Agents Market Revenue, By Imaging (2018-2026) ($Mn)
Table 141 RoW Medical Imaging Agents Market Revenue, By End-User, (2018-2026) ($Mn)
Table 142 RoW Medical Imaging Agents Market Revenue, By Country, (2018-2026) ($Mn)
Table 143 Collaboration, Agreement & Partnerships (2018-2019)
Table 144 Approvals (2018-2019)
Table 145 Bayer Group: Total Revenue And R&D Expenses (2017-2019) (Q2) ($Mn)
Table 146 Bayer Group: Total Revenue, By Segments (2017-2019) (Q2) ($Mn)
Table 147 Bayer Group: Total Revenue, By Geography (2017-2019) (Q2) ($Mn)
Table 148 Cardinal Health, Inc.: Total Revenue And R&D Expenses (2017-2019) ($Mn)
Table 149 Cardinal Health, Inc.: Total Revenue, By Segments, (2017-2019) ($Mn)
Table 150 Cardinal Health, Inc.: Total Revenue, By Geography, (2017-2019) ($Mn)
Table 151 Fujifilm Holding Corporation: Total Revenue And R&D Expenses, (2016 – 2018) ($Mn)
Table 152 Fujifilm Holding Corporation: Total Revenue, By Segments (2016-2018) ($Mn)
Table 153 Fujifilm Holding Corporation: Healthcare & Materials Revenue, By Sub-Segments (2016-2018) ($Mn)
Table 154 Fujifilm Holding Corporation: Total Revenue, By Geography (2016 – 2018) ($Mn)
Table 155 Fujipharma Co Ltd: Total Revenue And R&D Expenses, (2017–2019) (Q3) ($Mn)
Table 156 Fujipharma Co Ltd: Total Revenue, By Segments (2017-2019) (Q3) ($Mn)
Table 157 Fujipharma Co Ltd: Total Revenue, By Sub-Segments (2017-2019) (Q3) ($Mn)
Table 158 GE Company: Total Revenue And R&D Expenses (2017 – 2019) (Q2) ($Mn)
Table 159 GE Company: Total Revenue, By Segments (2017-2019) (Q2) ($Mn)
Table 160 GE Company: Total Revenue, By Healthcare Segment (2017 –2019) (Q2) ($Mn)
Table 161 GE Company: Total Revenue, By Geography (2017 –2019) (Q2) ($Mn)
Table 162 Guerbet: Total Revenue And R&D Expenses, (2017-2019) (Q2) ($Mn)
Table 163 Guerbet: Segmental Revenue (2017-2019) (Q2) ($Mn)
Table 164 Guerbet: Sub-Segmental Revenue (2017-2019) (Q2) ($Mn)
Table 165 Guerbet: Geographic Revenue (2017-2019) (Q2) ($Mn)
Table 166 Jubilant Lifescience: Total Revenue And R&D Expenses (2016–2018) ($Mn)
Table 167 Jubilant Lifescience: Total Revenue, By Segments (2016-2018) ($Mn)
Table 168 Jubilant Lifescience: Pharmaceutical Total Revenue, By Segments (2016-2018) ($Mn)
Table 169 Jubilant Lifescience: Spceialty Pharmaceutical Injectables Total Revenue, By Segments (2016-2018) ($Mn)
Table 170 Jubilant Lifescience: Total Revenue, By Geography (2016 – 2018) ($Mn)
Table 171 Lantheus Medical Imaging Inc.: Total Revenue And R&D Expenses, (2017-2019) (Q2) ($Mn)
Table 172 Lantheus Medical Imaging Inc.: Total Revenue, By Products (2017-2019) (Q2) ($Mn)
Table 173 Lantheus Medical Imaging Inc.: Total Revenue, By Geography (2017-2019) ($Mn)
Table 174 Novartis(Aaa): Total Revenue And R&D Expenses (2017-2019) (Q2) ($Mn)
Table 175 Novartis (Aaa): Total Revenue, By Segments (2017-2019) (Q2) ($Mn)
Table 176 Novartis (Aaa): Total Revenue, By Geography (2017-2019) (Q2) ($Mn)
List of Figures
Figure 1 Medical Imaging Agents Global Market Revenue, By Region (2018-2026) ($Mn)
Figure 2 Research Methodology: Medical Imaging Agents Global Market
Figure 3 Medical Imaging Agents Globalmarket: Top-Down And Bottom-Up Approach
Figure 4 Medical Imaging Agents Global Market: Forecasting Model
Figure 5 Medical Imaging Agents Global Market: Market Crackdown And Data Triangulation
Figure 6 Medical Imaging Agents Global Market: Market Segmentation
Figure 7 Market Dynamics
Figure 8 Technetium -99: Supply Chain Analysis
Figure 9 Contrast Agents Global Market: Supply Chain Analysis
Figure 10 Medicine Imaging Global Market: Pct Patent Filing By Major Players (2015-2019)
Figure 11 Medical Imaging Agents Global Market: Porter’S Analysis
Figure 12 Medical Imaging Agents Global Market Share Analysis, By Key Players, 2019 (%)
Figure 13 Contrast Agents Global Market Share Analysis, By Key Players, 2019 (%)
Figure 14 Nuclear Medicine Global Market Share Analysis, By Key Players, 2019 (%)
Figure 15 Mri Global Market Share Analysis, By Key Players, 2019 (%)
Figure 16 X-Ray/Ct Agents Global Market Share Analysis, By Key Players, 2019 (%)
Figure 17 Ultrasound Agents Global Market Share Analysis, By Key Players, 2019 (%)
Figure 18 Spect Agents Global Market Share Analysis, By Key Players, 2019 (%)
Figure 19 Pet Agents Global Market Share Analysis, By Key Players, 2019 (%)
Figure 20 Regional And Countrywise Consumption Of X-Ray/Ct Contrast Agents In Liters: (2019)(L)
Figure 21 Countrywise Consumption Of X-Ray/Ct Contrast Agents In Liters: (2019)(L)
Figure 22 Regional And Countrywise Consumption Of Mri Contrast Agents In Liters: (2019)(L)
Figure 23 Countrywise Consumption Of Mri Contrast Agents In Liters: (2019)(L)
Figure 24 Regional And Countrywise Consumption Of Ultrasound Contrast Agents In Liters: (2019)(L)
Figure 25 Countrywise Consumption Of Ultrasound Contrast Agents In Liters: (2019)(L)
Figure 26 Regional And Countrywise X-Ray/Ct Contrast Agents Procedural Volume: (2019)(No’S)
Figure 27 Regional And Countrywise Mri Contrast Agents Procedural Volume: (2019)(No’S)
Figure 28 Regional And Countrywise Ultrasound Contrast Agents Procedural Volume: (2019)(No’S)
Figure 29 Regional And Countrywise Spect Procedural Volume: (2019)(No’S)
Figure 30 Regional And Countrywise Pet Procedural Volume: (2019)(No’S)
Figure 31 Medical Imaging Agents Global Market Revenue, By Molecule/Isotope (2019 V/S 2026) ($Mn)
Figure 32 Contrast Agents Global Market Share, By Region (2019 V/S 2026) (%)
Figure 33 Contrast Agents Global Market Share, By Molecule (2019 V/S 2026) (%)
Figure 34 Iodinated Contrast Agents Global Market Share, By Region (2019 V/S 2026) (%)
Figure 35 Iodinated Contrast Agents Global Market Revenue, By Ionicity (2019 V/S 2026) ($Mn)
Figure 36 Iodinated Ionic Contrast Agents Global Market Share, By Region (2019 V/S 2026) (%)
Figure 37 Monomer Ionic Contrast Agents Global Market Share, By Region (2019 V/S 2026) (%)
Figure 38 Iodinated Non-Ionic Contrast Agents Global Market Share, By Region (2019 V/S 2026) (%)
Figure 39 Non-Ionic Contrast Agents Global Market Share, By Chemical Structure (2019 V/S 2026) (%)
Figure 40 Monomer Non-Ionic Contrast Agents Market Share, By Region (2019 V/S 2026) (%)
Figure 41 Gadolinium Based Contrast Agents Global Market Share, By Chemical Structure (2019 V/S 2026) (%)
Figure 42 Gadolinium Based Contrast Agents Market Share, By Region (2019 V/S 2026) (%)
Figure 43 Macrocyclic Contrast Agents Global Market Share, By Region (2019 V/S 2026) (%)
Figure 44 Macrocyclic Contrast Agents Global Market Share, By Ionicity (2019 V/S 2026) (%)
Figure 45 Non-Ionic Macrocyclic Contrast Agents Market Share, By Region (2019 V/S 2026) (%)
Figure 46 Microbubble Based Contrast Agents Global Market Share, By Region (2019 V/S 2026) (%)
Figure 47 Other Contrast Agents Global Market Share, By Region (2019 V/S 2026) (%)
Figure 48 Nuclear Medicine Global Market Share, By Region (2019 V/S 2026) (%)
Figure 49 Nuclear Imaging Agents Global Market Share, By Isotope (2019 V/S 2026) (%)
Figure 50 Technetium (Tc-99M) Isotope Global Market Share, By Region (2019 V/S 2026) (%)
Figure 51 Thallium (Tl-201) Isotope Global Market Share, By Region (2019 V/S 2026) (%)
Figure 52 Gallium (Ga-67) Isotope Global Market Share, By Region (2019 V/S 2026) (%)
Figure 53 Iodine (I-123) Isotope Global Market Share, By Region (2019 V/S 2026) (%)
Figure 54 Xenon (Xe-133) Isotope Global Market Share, By Region (2019 V/S 2026) (%)
Figure 55 Rhenium (Re-186) Isotope Global Market Share, By Region (2019 V/S 2026) (%)
Figure 56 Gallium (Ga-68) Isotope Global Market Share, By Region (2019 V/S 2026) (%)
Figure 57 Rubidium (Rb-82) Isotope Global Market Share, By Region (2019 V/S 2026) (%)
Figure 58 Medical Imaging Agents Global Market Share, By Modality (2019 V/S 2026) (%)
Figure 59 X-Ray/Ct Global Market Share, By Region (2019 V/S 2026) (%)
Figure 60 Ultrasound Global Market Share, By Region (2019 V/S 2026) (%)
Figure 61 Spect Global Market Share, By Region (2019 V/S 2026) (%)
Figure 62 Medical Imaging Agents Global Market Share, By Application (2019) (%)
Figure 63 Cardiovascular Global Market Share, By Region (2019 V/S 2026) (%)
Figure 64 Cancer Global Market Share, By Region (2019 V/S 2026) (%)
Figure 65 Gastrointestinal Global Market Share, By Region (2019 V/S 2026) (%)
Figure 66 Musculoskeletal Global Market Share, By Region (2019 V/S 2026) (%)
Figure 67 Nephrology Global Market Share, By Region (2019 V/S 2026) (%)
Figure 68 Obstetrics And Gynecology Global Market Share, By Region (2019 V/S 2026) (%)
Figure 69 Hepatology Global Market Share, By Region (2019 V/S 2026) (%)
Figure 70 Others Global Market Share, By Region (2019 V/S 2026) (%)
Figure 71 Medical Imaging Agents Global Market Share, By Route Of Administration (2019 V/S 2026) (%)
Figure 72 Intravascular Global Market Share, By Region (2019 V/S 2026) (%)
Figure 73 Oral Global Market Share, By Region (2019 V/S 2026) (%)
Figure 74 Rectal Administration Global Market Share, By Region (2019 V/S 2026) (%)
Figure 75 Others Global Market Share, By Region (2019 V/S 2026) (%)
Figure 76 Nuclear Medicine Application, Spect & Pet Isotopes
Figure 77 Medical Imaging Agents Global Market Share, By Imaging (2019 V/S 2026) (%)
Figure 78 Diagnostic Imaging Global Market Share, By Region (2019 V/S 2026) (%)
Figure 79 Medical Imaging Agents Global Market Share, By End-User (2019 V/S 2026) (%)
Figure 80 Hospital Global Market Share, By Region (2019 V/S 2026) (%)
Figure 81 Diagnostic & Ambulatory Centers Global Market Share, By Region (2019 V/S 2026) (%)
Figure 82 Medical Imaging Agents Global Market Revenue, By Region (2018-2026) ($Mn)
Figure 83 North America Medical Imaging Agents Market Share, By Molecule/Isotope (2019 V/S 2026) (%)
Figure 84 North America Contrast Agents By Molecule/Isotope And Iodinated Agents Market Revenue, By Ionicity (2019) ($Mn)
Figure 85 North America Non-Ionic Contrast Agents Market Share, By Chemical Structure (2019 V/S 2026) (%)
Figure 86 North America Gadolinium Based Contrast Agents Market Revenue, By Chemical Structure (2019 V/S 2026) ($Mn)
Figure 87 North America Macrocyclic Agents Market Revenue, By Ionicity (2019 V/S 2026) ($Mn)
Figure 88 North America Nuclear Medicine Market Revenue, By Isotope (2019 V/S 2026) ($Mn)
Figure 89 North America Medical Imaging Agents Market Share, By Modality (2019 V/S 2026) (%)
Figure 90 North America Medical Imaging Agents Market Share, By Application (2019) (%)
Figure 91 North America Medical Imaging Agents Market Share, By Route Of Administration (2019 V/S 2026) (%)
Figure 92 North America Medical Imaging Agents Market Share, By Imaging (2019 V/S 2026) (%)
Figure 93 North America Medical Imaging Agents Market Share, By End-User (2019 V/S 2026) (%)
Figure 94 North America Medical Imaging Agents Market Revenue, By Country (2019 V/S 2026) ($Mn)
Figure 95 U.S. Medical Imaging Agents Market Revenue, By Molecule/Isotopes (2019 V/S 2026) ($Mn)
Figure 96 U.S. Contrast Agents Market Revenue, By Molecule (2019 V/S 2026) ($Mn)
Figure 97 U.S. Nuclear Medicine Market Revenue, By Isotope (2019 V/S 2026) ($Mn)
Figure 98 U.S. Medical Imaging Agents Market Revenue, By Modality (2019 V/S 2026) ($Mn)
Figure 99 U.S. Medical Imaging Agents Market Revenue, By Application (2019) ($Mn)
Figure 100 U.S. Medical Imaging Agents Market Revenue, By Route Of Administration (2019 V/S 2026) ($Mn)
Figure 101 U.S. Medical Imaging Agents Market Revenue, By Imaging (2019 V/S 2026) ($Mn)
Figure 102 U.S. Medical Imaging Agents Market Revenue, By End-User (2019 V/S 2026) ($Mn)
Figure 103 Rest Of N.A. Medical Imaging Agents Market Revenue, By Molecule/Isotopes (2019 V/S 2026) ($Mn)
Figure 104 Rest Of N.A. Contrast Agents Market Revenue, By Molecule (2019 V/S 2026) ($Mn)
Figure 105 Rest Of N.A. Nuclear Medicine Market Revenue, By Isotope (2019 V/S 2026) ($Mn)
Figure 106 Rest Of N.A. Medical Imaging Agents Market Revenue, By Modality (2019 V/S 2026) ($Mn)
Figure 107 Rest Of N.A. Medical Imaging Agents Market Revenue, By Application (2019) ($Mn)
Figure 108 Rest Of N.A. Medical Imaging Agents Market Revenue, By Route Of Administration (2019 V/S 2026) ($Mn)
Figure 109 Rest Of N.A. Medical Imaging Agents Market Revenue, By Imaging (2019 V/S 2026) ($Mn)
Figure 110 Rest Of N.A. Medical Imaging Agents Market Revenue, By End-User (2019 V/S 2026) ($Mn)
Figure 111 Europe Medical Imaging Agents Market Share, By Molecule/Isotope (2019 V/S 2026) (%)
Figure 112 Europe Contrast Agents, By Molecule And Iodinated Agents Market Revenue, By Ionicity (2019) ($Mn)
Figure 113 Europe Non-Ionic Contrast Agents Market Share, By Chemical Structure (2019 V/S 2026) (%)
Figure 114 Europe Gadolinium Based Contrast Agents Market Revenue, Chemical Structure (2019 V/S 2026) ($Mn)
Figure 115 Europe Macrocyclic Contrast Agents Market Revenue, By Ionicity (2019 V/S 2026) ($Mn)
Figure 116 Europe Linear Agents Market Revenue, By Ionicity (2019 V/S 2026) ($Mn)
Figure 117 Europe Nuclear Medicine Market Share, By Isotope (2019 V/S 2026) (%)
Figure 118 Europe Medical Imaging Agents Market Share, By Modality (2019 V/S 2026) (%)
Figure 119 Europe Medical Imaging Agents Market Share, By Application (2019) (%)
Figure 120 Europe Medical Imaging Agents Market Share, By Route Of Administration (2019 V/S 2026) (%)
Figure 121 Europe Medical Imaging Agents Market Share, By Imaging (2019 V/S 2026) (%)
Figure 122 Europe Medical Imaging Agents Market Share, By End-User (2019 V/S 2026) (%)
Figure 123 Europe Medical Imaging Agents Market Revenue, By Country (2019 V/S 2026) ($Mn)
Figure 124 Germany Medical Imaging Agents Market Revenue, By Molecule/Isotope (2019 V/S 2026) ($Mn)
Figure 125 Germany Contrast Agents Market Revenue, By Molecule (2019 V/S 2026) ($Mn)
Figure 126 Germany Nuclear Medicine Market Revenue, By Isotope (2019 V/S 2026) ($Mn)
Figure 127 Germany Medical Imaging Agents Market Revenue, By Modality (2019 V/S 2026) ($Mn)
Figure 128 Germany Medical Imaging Agents Market Revenue, By Application (2019) ($Mn)
Figure 129 Germany Medical Imaging Agents Market Revenue, By Route Of Administration (2019 V/S 2026) ($Mn)
Figure 130 Germany Medical Imaging Agents Market Revenue, By Imaging (2019 V/S 2026) ($Mn)
Figure 131 Germany Medical Imaging Agents Market Revenue, By End-User (2019 V/S 2026) ($Mn)
Figure 132 France Medical Imaging Agents Market Revenue, By Molecule/Isotope (2019 V/S 2026) ($Mn)
Figure 133 France Contrast Agents Market Revenue, By Molecule (2019 V/S 2026) ($Mn)
Figure 134 France Nuclear Medicine Market Revenue, By Isotope (2019 V/S 2026) ($Mn)
Figure 135 France Medical Imaging Agents Market Revenue, By Modality (2019 V/S 2026) ($Mn)
Figure 136 France Medical Imaging Agents Market Revenue, By Application (2019) ($Mn)
Figure 137 France Medical Imaging Agents Market Revenue, By Route Of Administration (2019 V/S 2026) ($Mn)
Figure 138 France Medical Imaging Agents Market Revenue, By Imaging (2019 V/S 2026) ($Mn)
Figure 139 France Medical Imaging Agents Market Revenue, By End-User (2019 V/S 2026) ($Mn)
Figure 140 U.K. Medical Imaging Agents Market Revenue, By Molecule/Isotope (2019 V/S 2026) ($Mn)
Figure 141 U.K. Contrast Agents Market Revenue, By Molecule (2019 V/S 2026) ($Mn)
Figure 142 U.K. Nuclear Medicine Market Revenue, By Isotope (2019 V/S 2026) ($Mn)
Figure 143 U.K. Medical Imaging Agents Market Revenue, By Modality (2019 V/S 2026) ($Mn)
Figure 144 U.K. Medical Imaging Agents Market Revenue, By Application (2019) ($Mn)
Figure 145 U.K. Medical Imaging Agents Market Revenue, By Route Of Administration (2019 V/S 2026) ($Mn)
Figure 146 U.K. Medical Imaging Agents Market Revenue, By Imaging (2019 V/S 2026) ($Mn)
Figure 147 U.K. Medical Imaging Agents Market Revenue, By End-User (2019 V/S 2026) ($Mn)
Figure 148 Rest Of E.U. Medical Imaging Agents Market Revenue, By Molecule/Isotopes (2019 V/S 2026) ($Mn)
Figure 149 Rest Of E.U. Contrast Agents Market Revenue, By Molecule (2019 V/S 2026) ($Mn)
Figure 150 Rest Of E.U. Nuclear Medicine Market Revenue, By Isotope (2019 V/S 2026) ($Mn)
Figure 151 Rest Of E.U. Medical Imaging Agents Market Revenue, By Modality (2019 V/S 2026) ($Mn)
Figure 152 Rest Of E.U. Medical Imaging Agents Market Revenue, By Application (2019) ($Mn)
Figure 153 Rest Of E.U. Medical Imaging Agents Market Revenue, By Route Of Administration (2019 V/S 2026) ($Mn)
Figure 154 Rest Of E.U. Medical Imaging Agents Market Revenue, By Imaging (2019 V/S 2026) ($Mn)
Figure 155 Rest Of E.U. Medical Imaging Agents Market Revenue, By End-User (2019 V/S 2026) ($Mn)
Figure 156 APAC Medical Imaging Agents Market Share, Molecule/Isotope (2019 V/S 2026) (%)
Figure 157 APAC Contrast Agents, By Molecule/Isotope And Iodinated Market Revenue, By Ionicity (2019) ($Mn)
Figure 158 APAC Non-Ionic Contrast Agents Market Share, By Chemical Structure (2019 V/S 2026) (%)
Figure 159 APAC Gadolinium Based Contrast Agents Market Revenue, By Chemical Structure (2019 V/S 2026) ($Mn)
Figure 160 APAC Macrocyclic Constrast Agents Market Revenue, By Ionicity (2019 V/S 2026) ($Mn)
Figure 161 APAC Linear Contrast Agents Market Revenue, By Ionicity (2019 V/S 2026) ($Mn)
Figure 162 APAC Nuclear Medicine Market Share, By Isotope (2019 V/S 2026) (%)
Figure 163 APAC Medical Imaging Agents Market Share, By Modality (2019 V/S 2026) (%)
Figure 164 APAC Medical Imaging Agents Market Share, By Application (2019) (%)
Figure 165 APAC Medical Imaging Agents Market Share, By Route Of Administration (2019 V/S 2026) (%)
Figure 166 APAC Medical Imaging Agents Market Share, By Imaging (2019 V/S 2026) (%)
Figure 167 APAC Medical Imaging Agents Market Share, By End-User (2019 V/S 2026) (%)
Figure 168 APAC Medical Imaging Agents Market Revenue, By Country (2019 V/S 2026) ($Mn)
Figure 169 China Medical Imaging Agents Market Revenue, By Molecule/Isotope (2019 V/S 2026) ($Mn)
Figure 170 China Contrast Agents Market Revenue, By Molecule (2019 V/S 2026) ($Mn)
Figure 171 China Nuclear Medicine Market Revenue, By Isotope (2019 V/S 2026) ($Mn)
Figure 172 China Medical Imaging Agents Market Revenue, By Modality (2019 V/S 2026) ($Mn)
Figure 173 China Medical Imaging Agents Market Revenue, By Application (2019) ($Mn)
Figure 174 China Medical Imaging Agents Market Revenue, By Route Of Administration (2019 V/S 2026) ($Mn)
Figure 175 China Medical Imaging Agents Market Revenue, By Imaging (2019 V/S 2026) ($Mn)
Figure 176 China Medical Imaging Agents Market Revenue, By End-User (2019 V/S 2026) ($Mn)
Figure 177 Japan Medical Imaging Agents Market Revenue, By Molecule/Isotope (2019 V/S 2026) ($Mn)
Figure 178 Japan Contrast Agents Market Revenue, By Molecule (2019 V/S 2026) ($Mn)
Figure 179 Japan Nuclear Medicine Market Revenue, By Isotope (2019 V/S 2026) ($Mn)
Figure 180 Japan Medical Imaging Agents Market Revenue, By Modality (2019 V/S 2026) ($Mn)
Figure 181 Japan Medical Imaging Agents Market Revenue, By Application (2019) ($Mn)
Figure 182 Japan Medical Imaging Agents Market Revenue, By Route Of Administration (2019 V/S 2026) ($Mn)
Figure 183 Japan Medical Imaging Agents Market Revenue, By Imaging (2019 V/S 2026) ($Mn)
Figure 184 Japan Medical Imaging Agents Market Revenue, By End-User (2019 V/S 2026) ($Mn)
Figure 185 South Korea Medical Imaging Agents Market Revenue, By Molecule/Isotope (2019 V/S 2026) ($Mn)
Figure 186 South Korea Contrast Agents Market Revenue, By Molecule (2019 V/S 2026) ($Mn)
Figure 187 South Korea Nuclear Medicine Market Revenue, By Isotope (2019 V/S 2026) ($Mn)
Figure 188 South Korea Medical Imaging Agents Market Revenue, By Modality (2019 V/S 2026) ($Mn)
Figure 189 South Korea Medical Imaging Agents Market Revenue, By Application (2019) ($Mn)
Figure 190 South Korea Medical Imaging Agents Market Revenue, By Route Of Administration (2019 V/S 2026) ($Mn)
Figure 191 South Korea Medical Imaging Agents Market Revenue, By Imaging (2019 V/S 2026) ($Mn)
Figure 192 South Korea Medical Imaging Agents Market Revenue, By End-User (2019 V/S 2026) ($Mn)
Figure 193 Rest Of APAC Medical Imaging Agents Market Revenue, By Molecule/Isotope (2019 V/S 2026) ($Mn)
Figure 194 Rest Of APAC Contrast Agents Market Revenue, By Molecule (2019 V/S 2026) ($Mn)
Figure 195 Rest Of APAC Nuclear Medicine Market Revenue, By Isotope (2019 V/S 2026) ($Mn)
Figure 196 Rest Of APAC Medical Imaging Agents Market Revenue, By Modality (2019 V/S 2026) ($Mn)
Figure 197 Rest Of APAC Medical Imaging Agents Market Revenue, By Application (2019) ($Mn)
Figure 198 Rest Of APAC Medical Imaging Agents Market Revenue, By Route Of Administration (2019 V/S 2026) ($Mn)
Figure 199 Rest Of APAC Medical Imaging Agents Market Revenue, By Imaging (2019 V/S 2026) ($Mn)
Figure 200 Rest Of APAC Medical Imaging Agents Market Revenue, By End-User (2019 V/S 2026) ($Mn)
Figure 201 RoW Medical Imaging Agents Market Share, By Molecule/Isotope (2019 V/S 2026) (%)
Figure 202 RoW Contrast Agents By Molecule And Iodinated Agents Market Revenue, By Ionicity (2019) ($Mn)
Figure 203 RoW Non-Ionic Contast Agents Market Share, By Chemical Structure (2019 V/S 2026) (%)
Figure 204 RoW Gadolinum Based Contrast Agents Market Revenue, By Chemical Structure (2019 V/S 2026) ($Mn)
Figure 205 RoW Macrocyclic Agents Market Revenue, By Ionicity (2019 V/S 2026) ($Mn)
Figure 206 RoW Linear Agents Market Revenue, By Ionicity (2019 V/S 2026) ($Mn)
Figure 207 RoW Nuclear Medicine Market Share, By Isotope (2019 V/S 2026) (%)
Figure 208 RoW Medical Imaging Agents Market Share, By Modality (2019 V/S 2026) (%)
Figure 209 RoW Medical Imaging Agents Market Share, By Application (2019 V/S 2026) (%)
Figure 210 RoW Medical Imaging Agents Market Share, By Route Of Administration (2019 V/S 2026) (%)
Figure 211 RoW Medical Imaging Agents Market Share, By Imaging (2019 V/S 2026) (%)
Figure 212 RoW Medical Imaging Agents Market Share, By End-User (2019 V/S 2026) (%)
Figure 213 RoW Medical Imaging Agents Market Revenue, By Country (2019 V/S 2026) ($Mn)
Figure 214 Turkey Medical Imaging Agents Market Revenue, By Molecule/Isotope (2019 V/S 2026) ($Mn)
Figure 215 Turkey Contrast Agents Market Revenue, By Molecule (2019 V/S 2026) ($Mn)
Figure 216 Turkey Medical Imaging Agents Market Revenue, By Isotope (2019 V/S 2026) ($Mn)
Figure 217 Turkey Medical Imaging Agents Market Revenue, By Modality (2019 V/S 2026) ($Mn)
Figure 218 Turkey Medical Imaging Agents Market Revenue, By Application (2019) ($Mn)
Figure 219 Turkey Medical Imaging Agents Market Revenue, By Route Of Administration (2019 V/S 2026) ($Mn)
Figure 220 Turkey Medical Imaging Agents Market Revenue, By Imaging (2019 V/S 2026) ($Mn)
Figure 221 Turkey Medical Imaging Agents Market Revenue, By End-User (2019 V/S 2026) ($Mn)
Figure 222 Brazil Medical Imaging Agents Market Revenue, By Molecule/Isotope (2019 V/S 2026) ($Mn)
Figure 223 Brazil Contrast Agents Market Revenue, By Molecule (2019 V/S 2026) ($Mn)
Figure 224 Brazil Nuclear Medicine Market Revenue, By Isotope (2019 V/S 2026) ($Mn)
Figure 225 Brazil Medical Imaging Agents Market Revenue, By Modality (2019 V/S 2026) ($Mn)
Figure 226 Brazil Medical Imaging Agents Market Revenue, By Application (2019) ($Mn)
Figure 227 Brazil Medical Imaging Agents Market Revenue, By Route Of Administration (2019 V/S 2026) ($Mn)
Figure 228 Brazil Medical Imaging Agents Market Revenue, By Imaging (2019 V/S 2026) ($Mn)
Figure 229 Brazil Medical Imaging Agents Market Revenue, By End-User (2019 V/S 2026) ($Mn)
Figure 230 Others Medical Imaging Agents Market Revenue, By Molecule/Isotope (2019 V/S 2026) ($Mn)
Figure 231 Others Iodinated Contrast Agents Market Revenue, By Molecule (2019 V/S 2026) ($Mn)
Figure 232 Others Nuclear Medicine Market Revenue, By Isotope (2019 V/S 2026) ($Mn)
Figure 233 Others Medical Imaging Agents Market Revenue, By Modality (2019 V/S 2026) ($Mn)
Figure 234 Others Medical Imaging Agents Market Revenue, By Application (2019) ($Mn)
Figure 235 Others Medical Imaging Agents Market Revenue, By Route Of Administration (2019 V/S 2026) ($Mn)
Figure 236 Others Medical Imaging Agents Market Revenue, By Imaging (2019 V/S 2026) ($Mn)
Figure 237 Others Medical Imaging Agents Market Revenue, By End-User (2019 V/S 2026) ($Mn)
Figure 238 Key Growth Strategies (2016 – 2018)
Figure 239 SWOT: Bayer Group
Figure 240 SWOT: Bracco Group
Figure 241 SWOT: Cardinal Health, Inc.
Figure 242 SWOT: Curium Pharma
Figure 243 SWOT: Fujifilm Holding Corporation
Figure 244 SWOT: Fujipharma Co Ltd
Figure 245 SWOT: GE Healthcare
Figure 246 SWOT: Guerbet
Figure 247 SWOT: Jubilant Lifescience
Figure 248 SWOT: Lantheus Medical Imaging Inc.
Figure 249 SWOT: Novartis (Aaa)
LOADING...
- Avid Radiopharmaceuticals, Inc (Eli Lilly and Company)
- Advanced Accelerator Applications Sa (Novartis Co.)
- Arronax-Nantes
- Australian Nuclear Science and Technology Organization
- Bayer Group
- Beijing Beilu Pharmaceuticals Company Limited
- Biem Pharmaceuticals
- Bracco Imaging S.P.A.
- BV Cyclotron
- Canadian Isotope Innovations Corp.
- Cardinal Health
- Center of Molecular Research
- Centre For Probe Development And Commercialization
- China National Nuclear Corporation (China Isotope & Radiation Corporation)
- Curium Pharma
- Daihan Pharma Co Ltd
- Dongkook Lifescience
- Eckert & Ziegler Strahlen
- Eczacibasi-Monrol Nuclear Products
- Fluoro Pharma
- Fujifilm Corporation
- Fujipharma Co Ltd
- Futurechem Co. Ltd
- Galenica Senese S.R.L
- GE Healthcare
- Graton Pharma
- Guerbet
- Hana Pharm Co., Ltd
- Harmony Life Sciences
- Huayi Technology Co., Ltd (Huayi Isotopes Co)
- Imax Diagnostic Imaging Limited
- Institute Of Isotopes
- International Isotopes Inc.
- Iso-Analytical Ltd.
- Isorad Ltd
- Iso-Tex Diagnostics Inc.
- Isotopia Molecular Imaging Ltd.
- I-Themba Labs
- JB Chemicals And Pharmaceuticals Ltd
- Jodas Expoim Pvt. Ltd
- JSC Isotope
- Jubilant Lifescience
- Lantheus Medical Imaging
- Magnus Health
- Medical Isotopes
- Nano Therapeutics
- National Institute For Radioelements (Ire)
- Nihon Medi Physics Co Ltd
- Nuclear Research And Consultancy Group (Nrg)
- Otsuka Pharmaceutical Co., Ltd
- Pars Isotope
- Perma-Fix Medical S.A.
- Pharmalucence Inc.
- Rege Imaging & Cinefilms Private Limited
- Rotop Pharmaka Gmbh
- Samyoung Unitech
- Sanochemia
- Shine Medical Technologies, Inc
- Solcom Limited
- South African Nuclear Energy Corporation (Ntp Radioisotopes Soc Ltd)
- Stryker(Novadaq Technologies)
- Swan Isotopen AG
- Taejoon Pharm Co. Ltd.,
- Trivitron Healthcare
- Unijules Life Sciences Ltd
- Unimark Remedies
- Zag Zyklotron AG
- Zhejiang Starry Pharma
LOADING...
